Lipid-Lowering Medication and Risk of Injury

Archived Abstract of Former PSC Researcher

Bovbjerg, Viktor E., David S. Siscovick, Bruce M. Psaty, Barbara S. McCann, Thomas D. Koepsell, Trivellore Raghunathan, and Edward H. Wagner. 1999. "Lipid-Lowering Medication and Risk of Injury." Journal of Clinical Epidemiology, 52(12): 1197-1200.

Meta-analyses of early primary prevention trials of lipid-lowering therapies suggested increased risk of injury deaths among treated persons. Our population-based case-control study examined the association of lipid-lowering medication use with fatal and nonfatal injuries in 298 cases and 332 controls. No increased injury risk was observed among current (OR = 0.46, 95% CI 0.18-1.21) or past users (OR = .92, 95% CI 0.44-1.95), after adjustment for behavioral disorders, medical conditions, and health status. Stratified analyses did not reveal sub-groups at significantly increased risk. These results, consistent with recent clinical trials and meta-analyses, suggest no increased injury risk associated with lipid-lowering medications.

http://www.sciencedirect.com/science/article/B6T84-3XWJR9Y-9/2/68f47d9abc04694592d63befd6631849

Keywords:
Anticholesterolemic agents cholesterol lipoproteins injury coronary disease case-control study

Browse | Search | Next

PSC In The News

RSS Feed icon

Shaefer comments on the Cares Act impact in negating hardship during COVID-19 pandemic

Heller comments on lasting safety benefit of youth employment programs

More News

Highlights

Dean Yang's Combatting COVID-19 in Mozambique study releases Round 1 summary report

Help Establish Standard Data Collection Protocols for COVID-19 Research

More Highlights


Connect with PSC follow PSC on Twitter Like PSC on Facebook